Chris Schott
Stock Analyst at JP Morgan
(0)
# 3175
Out of 5,240 analysts
124
Total ratings
40.85%
Success rate
4.11%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Maintains: Overweight | 210 200 | 175.46 | 13.99% | 2 | Nov 13, 2024 | |
Gilead Sciences | Maintains: Overweight | 100 105 | 91 | 15.38% | 3 | Nov 7, 2024 | |
Biogen | Maintains: Neutral | 220 210 | 143 | 46.85% | 3 | Nov 4, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1200 1150 | 690.23 | 66.61% | 5 | Oct 24, 2024 | |
Teva Pharmaceutical ... | Maintains: Neutral | 16 18 | 21 | -14.29% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 418.22 | 37.49% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 164.36 | 39.94% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 743.02 | 48.04% | 19 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 15.84 | 26.26% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 9 | 7.86 | 14.5% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 23.51 | 74.39% | 8 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 30.07 | 39.67% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 267 | 1.12% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 26.41 | 28.74% | 7 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 99.64 | 25.45% | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 11.71 | 19.56% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 1.45 | 658.62% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 11.69 | 71.09% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 55.74 | 39.94% | 4 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 6.65 | 14185.71% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 20.55 | 143.31% | 3 | Nov 2, 2018 |